Rafferty Asset Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Rafferty Asset Management’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.39M	Sell	101,655 -63,776	-39%	-$1.58M	0.01%	496
2026 Q1	$3.47M	Buy	165,431 +8,370	+5%	+$188K	0.01%	491
2025 Q4	$3.61M	Buy	157,061 +577	+0.4%	+$19K	0.01%	521
2025 Q3	$4.71M	Buy	156,484 +75,388	+93%	+$2.26M	0.02%	439
2025 Q2	$2.95M	Sell	81,096 -7,716	-9%	-$278K	0.01%	505
2025 Q1	$3.22M	Sell	88,812 -12,481	-12%	-$519K	0.01%	464
2024 Q4	$4.26M	Buy	101,293 +2,892	+3%	+$143K	0.02%	446
2024 Q3	$5.47M	Sell	98,401 -27,758	-22%	-$1.41M	0.02%	403
2024 Q2	$5.19M	Sell	126,159 -55,325	-30%	-$2.36M	0.02%	407
2024 Q1	$8.47M	Sell	181,484 -40,426	-18%	-$1.91M	0.03%	333
2023 Q4	$10.6M	Buy	221,910 +38,859	+21%	+$1.51M	0.04%	260
2023 Q3	$6.53M	Buy	183,051 +21,376	+13%	+$847K	0.04%	334
2023 Q2	$7.46M	Sell	161,675 -13,900	-8%	-$645K	0.04%	311
2023 Q1	$7.04M	Sell	175,575 -22,725	-11%	-$975K	0.05%	292
2022 Q4	$9.19M	Buy	198,300 +57,610	+41%	+$2.27M	0.08%	199
2022 Q3	$5.83M	Buy	140,690 +64,107	+84%	+$3.29M	0.06%	302
2022 Q2	$4.57M	Sell	76,583 -5,154	-6%	-$317K	0.04%	292
2022 Q1	$5.94M	Buy	81,737 +14,046	+21%	+$977K	0.04%	336
2021 Q4	$5.69M	Buy	67,691 +37,052	+121%	+$3.01M	0.03%	330
2021 Q3	$2.76M	Buy	30,639 +4,993	+19%	+$451K	0.02%	527
2021 Q2	$2.44M	Sell	25,646 -599	-2%	-$62.4K	0.02%	618
2021 Q1	$2.99M	Buy	26,245 +19,812	+308%	+$2.7M	0.02%	500
2020 Q4	$891K	Sell	6,433 -20,440	-76%	-$2.42M	0.01%	533
2020 Q3	$2.21M	Buy	26,873 +12,840	+91%	+$1.06M	0.03%	382
2020 Q2	$1.1M	Buy	14,033 +7,335	+110%	+$485K	0.02%	515
2020 Q1	$298K	Sell	6,698 -50,227	-88%	-$2.61M	0.01%	439
2019 Q4	$2.43M	Sell	56,925 -41,882	-42%	-$1.73M	0.04%	306
2019 Q3	$4.23M	Buy	98,807 +12,306	+14%	+$669K	0.07%	174
2019 Q2	$5.49M	Buy	86,501 +21,478	+33%	+$1.37M	0.1%	141
2019 Q1	$4.51M	Buy	+65,023	New	+$3.72M	0.07%	155

Other funds holding RARE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Rafferty Asset Management's RARE Position: Q2 2026 in Review

Rafferty Asset Management reduced its Ultragenyx Pharmaceutical (RARE) stake by 39% in Q2 2026, selling an estimated $1.58M and leaving 101,655 shares worth $3.39M. The position accounts for 0.01% of the portfolio, ranked #496.

Rafferty Asset Management first reported a position in RARE in Q1 2019 and has held it in 30 quarters since. The position peaked at $10.6M in Q4 2023. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

Rafferty Asset Management held 101,655 shares of Ultragenyx Pharmaceutical worth $3.39M as of Q2 2026.
Rafferty Asset Management sold 63,776 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $1.58M.
Ultragenyx Pharmaceutical made up 0.01% of Rafferty Asset Management's portfolio in Q2 2026, its #496 holding.
Rafferty Asset Management first reported a position in Ultragenyx Pharmaceutical in Q1 2019 and has held it in 30 quarters since.
Rafferty Asset Management's Ultragenyx Pharmaceutical position peaked at $10.6M in Q4 2023.
311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Rafferty Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.